Immunotherapy for early triple negative breast cancer
Due to its aggressive nature and lack of actionable targets, triple negative breast cancer (TNBC) has historically been a difficult illness to treat. Pembrolizumab has been established as the new standard of treatment in this situation due to studies showing that it greatly increases event-free survival for stage II-III TNBC when combined with neoadjuvant chemotherapy. However, this significant development has brought up some crucial scientific issues. In fact, we urgently need methods for early detection of individuals who will benefit from the inclusion of immunotherapy. Additionally, the ideal way to combine pembrolizumab with additional new developments (capecitabine, olaparib) has not yet been determined. Last but not least, significant efforts are required to reduce the financial toxicity and adverse immunological events' effects on patients. To overcome these difficulties and finally discover the best way to include immunotherapy into the continuum of TNBC treatment, the next ten years of clinical study will be crucial.
.png)
Reference: Tarantino P, Corti C, Schmid P, et al. Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ Breast Cancer. 2022;8(1):23. Published 2022 Feb 18. doi:10.1038/s41523-022-00386-1
You may also be interested in:
The Wonderful Collision of "Classic Target CTLA-4" and "Immunotherapy Star CD47"
Modified 'Toxoplasma' Makes Immunotherapy More Effective Against 'Cold' Tumors
